newsfilter
← Latest News
GlobeNewswire·

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of